Clinical applications and future directions of Iodine-131-Metaiodobenzylguanidine therapy in neuroblastoma: from salvage treatment to frontline integration.

Ann Nucl Med · 2026 · PMC12935704 · PMID 41528635

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Clinically, this group showed a trend toward higher 2-year event-free survival (40% vs. 16.7%), although the cohort size was limited.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.